Somatic activation of KIT in distinct subtypes of melanoma.

By J. Curtin, K. Busam, Dan Pinkel, B. Bastian. Journal of Clinical Oncology, 2006

1,558 citations recorded by the source corpus.

Subfields: Gastroenterology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/53ec16248f39f996622a72f81b11288195329cd6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Eric S. Lander
2. Gad Getz
3. Scott L. Carter
4. Matthew Meyerson
5. Todd R. Golub
6. Levi A. Garraway
7. Stacey Gabriel
8. Nicolas Stransky

In Oncology

1. D. Pardoll
2. Lieping Chen
3. S. Topalian
4. Janis Taube
5. J. Wargo
6. A. Klein
7. Gad Getz
8. Nicolas Stransky

Citations in the corpus

• Cancer genomics: from discovery science to personalized medicine (2011, background): “Some notable ones include kinase-activating mutations in the oncogene KIT and fibroblast growth factor receptor 2 ( FGFR2 ) in acral or mucosal melanoma and endometrial carcinoma, respectivel”
• NRAS Mutation Status is an Independent Prognostic Factor in Metastatic Melanoma (2011, background): “Finally, additional genetic aberrations may characterize each of the mutation-defined cohorts here, such as loss of phosphatase and tensin homolog (PTEN)(22) or activating c-KITmutations.(23) The emergence of BRAF-targeted therapies that benefit only patients with activating BRAFmutations will almos”
• Melanoma genome sequencing reveals frequent PREX2 mutations (2012, positive): “KIT mutations occur in 15% of acral and mucosal melanomas 12 , and melanoma patients with activating KIT mutations in exon 11 have demonstrated marked responses to imatinib treatment 13 .”
• KIT as a therapeutic target in metastatic melanoma. (2011, neutral): “Mucosal Ex 9 N463S No 1:1 NA Mucosal Ex 11 L576Pa Yes (>10) 1:1 Mixed Mucosal Ex 11 L576Pa Yes (5-10) 1:1 Mixed”
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012, background): “Most patients had the acral lentiginous subtype of melanoma, which is associated with c-Kit mutations, rather than with BRAF mutations, which predominate in cohorts of European descent (51, 52).”